Company intelligence / Profile preview

Fuse Biotherapeutics

Los Angeles, California, United Statesfusebiotx.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Fuse Biotherapeutics is developing immune-modulating therapeutics designed to enhance the body's immune response to cancer while sparing healthy tissue. Their approach leverages multi-functional antibodies that activate NK cells only in the presence of diseased tissue, aiming for potent anti-tumor activity with reduced toxicity. As of 2024, there are no reported clinical results; the company remains at a preclinical development stage[1][2][5].

Therapeutic areas: Oncology
Modalities: Multi-functional antibodiesImmune-modulating biologics (focus on NK cell and T cell biology)[2][5]
Industry: Biotech

Drug pipeline

1 asset

PD1-F18

Pre-clinical

Indications: Cancer, Solid tumors

Partnerships

Viva BioInnovator/Viva Biotech (lead investor and incubator support)[5]

Beyond the preview

Go deeper on Fuse Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fuse Biotherapeutics.

Explore the full profile